Another active phase Ib study (NCT04042701) is assessing the combination of T-DXd and ICI, pembrolizumab, in HER2-mutant and HER2-positive NSCLC patients who have not previously received HER2-targeted or anti-PD-1/PD-L1 therapies (137). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.